Chelsea Therapeutics

Chelsea Therapeutics International, Ltd. is a development-stage pharmaceutical company focused on acquiring, developing, and commercializing products for the treatment of various human diseases. The company is developing therapeutic agents for symptomatic neurogenic orthostatic hypotension (NOH) and related conditions and diseases, as well as prescription products for multiple autoimmune diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. As of December 31, 2009, it concentrated its drug development resources on two clinical-stage development programs: droxidopa for symptomatic NOH and other potential indications, and a combination of non-metabolizable antifolate compounds for the treatment of rheumatoid arthritis.